Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
AGIOS PHARM (NASDAQ: AGIO) Delayed: 35.10 --0 (-0%)
Previous Close $35.10    52 Week High $71.49 
Open $35.10    52 Week Low $33.50 
Day High $35.10    P/E N/A 
Day Low $35.10    EPS $-1.18 
Volume 121